Patents by Inventor Steven G. Reed

Steven G. Reed has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of using a vaccine composition containing synthetic adjuvant
    Patent number: 8609114
    Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.
    Type: Grant
    Filed: August 30, 2012
    Date of Patent: December 17, 2013
    Assignee: Infectious Diesease Research Institute
    Inventor: Steven G. Reed
  • VACCINES AGAINST TOXOPLASMA GONDII
    Publication number: 20130273094
    Abstract: Vaccines are disclosed against parasites. The vaccines include peptides in an immunological composition. In particular, the parasite is Toxoplas gondii.
    Type: Application
    Filed: November 3, 2011
    Publication date: October 17, 2013
    Applicants: THE UNIVERSITY OF CHICAGO, PAXVAX, INC., INFECTIOUS DISEASE RESEARCH INSTITUTE
    Inventors: Rima McLeod, Tze Guan Tan, Jeffery L. Alexander, Hua Cong, William H. Witola, Kamal El Bissati, Ernest J. Mui, Steven G. Reed
  • Immunogenic compositions comprising polypeptides and fusions thereof
    Patent number: 8486414
    Abstract: The present invention relates to compositions and fusion proteins containing at least two Mycobacterium sp. antigens, and polynucleotides encoding such compositions and fusion proteins. The invention also relates to methods for their use in the treatment, prevention and/or diagnosis of tuberculosis infection.
    Type: Grant
    Filed: April 4, 2008
    Date of Patent: July 16, 2013
    Assignee: Infectious Disease Research Institute
    Inventors: Steven G. Reed, Rhea N. Coler, Gregory C. Ireton, Sylvie Bertholet
  • Recombinant Polyprotein Vaccines For the Treatment and Diagnosis of Leishmaniasis
    Publication number: 20130177584
    Abstract: Compositions and methods for preventing, treating and detecting leishmaniasis are disclosed. The compositions generally comprise fusion polypeptides comprising multiple Leishmania antigens, in particular, KMP11, SMT, A2 and/or CBP, or immunogenic portions or variants thereof, as well as polynucleotides encoding such fusion polypeptides.
    Type: Application
    Filed: March 12, 2013
    Publication date: July 11, 2013
    Applicant: INFECTIOUS DISEASE RESEARCH INSTITUTE
    Inventors: Yasuyuki Goto, Steven G. Reed
  • Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis
    Patent number: 8425919
    Abstract: Compositions and methods for preventing, treating and detecting leishmaniasis are disclosed. The compositions generally comprise fusion polypeptides comprising multiple Leishmania antigens, in particular, KMP11, SMT, A2 and/or CBP, or immunogenic portions or variants thereof, as well as polynucleotides encoding such fusion polypeptides.
    Type: Grant
    Filed: May 15, 2009
    Date of Patent: April 23, 2013
    Assignee: Infectious Disease Research Institute
    Inventors: Yasuyuki Goto, Steven G. Reed
  • VACCINE COMPOSITION CONTAINING SYNTHETIC ADJUVANT
    Publication number: 20130084307
    Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.
    Type: Application
    Filed: August 30, 2012
    Publication date: April 4, 2013
    Applicant: Infectious Disease Research Institute
    Inventors: STEVEN G. REED, Darrick Carter
  • Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis
    Patent number: 8410258
    Abstract: Compositions and methods for preventing, treating and detecting leishmaniasis are disclosed. The compositions generally comprise fusion polypeptides comprising multiple Leishmania antigens, in particular, KMP11, SMT, A2 and/or CBP, or immunogenic portions or variants thereof, as well as polynucleotides encoding such fusion polypeptides.
    Type: Grant
    Filed: November 18, 2009
    Date of Patent: April 2, 2013
    Assignee: Infections Disease Research Institute
    Inventors: Yasuyuki Goto, Steven G. Reed
  • FUSION PROTEINS AND THEIR USE IN THE DIAGNOSIS AND TREATMENT OF LEISHMANIASIS
    Publication number: 20130071862
    Abstract: The present invention relates generally to a fusion protein made from a synthetic gene construct comprising of elements derived from the Leishmania antigens K26, K39, and K9. The fusion protein is particularly useful in the diagnosis of leishmaniasis, particularly visceral leishmaniasis in animals such as humans and dogs.
    Type: Application
    Filed: July 27, 2012
    Publication date: March 21, 2013
    Applicant: INFECTIOUS DISEASE RESEARCH INSTITUTE
    Inventors: Ajay Bhatia, Steven G. Reed
  • VACCINE COMPOSITION CONTAINING SYNTHETIC ADJUVANT
    Publication number: 20130058997
    Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.
    Type: Application
    Filed: August 30, 2012
    Publication date: March 7, 2013
    Applicant: Infectious Disease Research Institute
    Inventors: STEVEN G. REED, Darrick Carter
  • Treatment of allergic conditions using a composition containing synthetic adjuvant
    Patent number: 8343512
    Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.
    Type: Grant
    Filed: October 20, 2011
    Date of Patent: January 1, 2013
    Assignee: Infectious Disease Research Institute
    Inventors: Steven G. Reed, Darrick Carter
  • Vaccine composition containing synthetic adjuvant
    Patent number: 8273361
    Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.
    Type: Grant
    Filed: September 26, 2007
    Date of Patent: September 25, 2012
    Assignee: Infectious Disease Research Institute
    Inventors: Steven G. Reed, Darrick Carter
  • Fusion proteins and their use in the diagnosis and treatment of leishmaniasis
    Patent number: 8231881
    Abstract: The present invention relates generally to a fusion protein made from a synthetic gene construct comprising of elements derived from the Leishmania antigens K26, K39, and K9. The fusion protein is particularly useful in the diagnosis of leishmaniasis, particularly visceral leishmaniasis in animals such as humans and dogs.
    Type: Grant
    Filed: July 2, 2009
    Date of Patent: July 31, 2012
    Assignee: Infectious Disease Research Institute
    Inventors: Ajay Bhatia, Steven G. Reed
  • COMPOUNDS AND METHODS FOR IMMUNOTHERAPY AND DIAGNOSIS OF TUBERCULOSIS
    Publication number: 20120171248
    Abstract: Compounds and methods for inducing protective immunity against tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more M. tuberculosis proteins and DNA molecules encoding such polypeptides. Such compounds may be formulated into vaccines and/or pharmaceutical compositions for immunization against M. tuberculosis infection, or may be used for the diagnosis of tuberculosis.
    Type: Application
    Filed: October 29, 2007
    Publication date: July 5, 2012
    Applicant: CORIXA CORPORATION
    Inventors: Steven G. Reed, Yasir A.W. Skeiky, Davin C. Dillon, Antonio Campos-Neto, Raymond Houghton, Thomas S. Vedvick, Daniel R. Twardzik, Michael J. Lodes, Ronald C. Hendrickson
  • VACCINES COMPRISING NON-SPECIFIC NUCLEOSIDE HYDROLASE AND STEROL 24-C-METHYLTRANSFERASE (SMT) POLYPEPTIDES FOR THE TREATMENT AND DIAGNOSIS OF LEISHMANIASIS
    Publication number: 20120114688
    Abstract: Compositions and methods for preventing, treating and detecting leishmaniasis are disclosed. The compositions generally comprise fusion polypeptides comprising Leishmania antigens, in particular, SMT and NH antigens or immunogenic portions or variants thereof, as well as polynucleotides encoding such fusion polypeptides.
    Type: Application
    Filed: November 7, 2011
    Publication date: May 10, 2012
    Applicant: INFECTIOUS DISEASE RESEARCH INSTITUTE
    Inventors: Ajay Bhatia, Steven G. Reed
  • Methods and materials for the detection of infection
    Patent number: 8173383
    Abstract: The present invention provides rapid diagnostic assays for the detection of Leishmania which can readily be used in the field, leading to more rapid treatment. In certain embodiments, the inventive assays, including ELISA and lateral flow assays, employ antibodies that may be effectively employed to detect the Leishmania major antigen TSA, which is present in both promastigotes grown in culture and in amastigotes. Such assays may be employed to detect the presence of cutaneous leishmaniasis in a subject using scrapings, biopsies, and/or aspirates taken from cutaneous lesions.
    Type: Grant
    Filed: January 24, 2011
    Date of Patent: May 8, 2012
    Assignee: InBios International, Inc.
    Inventors: Raymond L. Houghton, Steven G. Reed, Syamal Raychaudhuri
  • Fusion proteins of antigens and their uses
    Patent number: 8143386
    Abstract: The present invention relates to fusion proteins containing at least two Mycobacterium tuberculosis antigens. In particular, it relates to bi-fusion proteins which contain two individual M. tuberculosis antigens, tri-fusion proteins which contain three M. tuberculosis antigens, tetra-fusion proteins which contain four M. tuberculosis antigens, and penta-fusion proteins which contain five M. tuberculosis antigens, and methods for their use in the diagnosis, treatment and prevention of tuberculosis infection.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: March 27, 2012
    Assignee: Corixa Corporation
    Inventors: Steven G. Reed, Yasir A. Skeiky, Davin C. Dillon, Mark Alderson, Antonio Campos-Nero
  • VACCINE COMPOSITION CONTAINING SYNTHETIC ADJUVANT
    Publication number: 20120039994
    Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.
    Type: Application
    Filed: October 20, 2011
    Publication date: February 16, 2012
    Applicant: Infectious Disease Research Institute
    Inventors: Steven G. Reed, Darrick Carter
  • Compounds and methods for immunotherapy and diagnosis of tuberculosis
    Patent number: 8084042
    Abstract: Compounds and methods for inducing protective immunity against tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more M. tuberculosis proteins and DNA molecules encoding such polypeptides. Such compounds may be formulated into vaccines and/or pharmaceutical compositions for immunization against M. tuberculosis infection, or may be used for the diagnosis of tuberculosis.
    Type: Grant
    Filed: May 7, 2007
    Date of Patent: December 27, 2011
    Assignee: Corixa Corporation
    Inventors: Steven G. Reed, Yasir A. W. Skeiky, Davin C. Dillon, Antonio Campos-Neto, Raymond Houghton, Thomas S. Vedvick, Daniel R. Twardzik, Michael J. Lodes, Ronald C. Hendrickson
  • Vaccines for Pandemic Influenza
    Publication number: 20110305748
    Abstract: Pharmaceutical and vaccine compositions comprise recombinant hemagglutinin from a pre-pandemic or pandemic influenza virus and an adjuvant comprising GLA. A particularly relevant pre-pandemic influenza virus is H5N1. Kits and methods of using the compositions are also provided.
    Type: Application
    Filed: March 10, 2011
    Publication date: December 15, 2011
    Applicant: IMMUNE DESIGN, CORP.
    Inventors: Christopher H. Clegg, Steven G. Reed, Neal Van Hoeven
  • COMPOUNDS AND METHODS FOR IMMUNOTHERAPY AND DIAGNOSIS OF TUBERCULOSIS
    Publication number: 20110305721
    Abstract: Compounds and methods for inducing protective immunity against tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more M. tuberculosis proteins and DNA molecules encoding such polypeptides. Such compounds may be formulated into vaccines and/or pharmaceutical compositions for immunization against M. tuberculosis infection, or may be used for the diagnosis of tuberculosis.
    Type: Application
    Filed: May 4, 2011
    Publication date: December 15, 2011
    Applicant: CORIXA CORPORATION
    Inventors: Steven G. Reed, Yasir A. W. Skeiky, Davin C. Dillon, Antonio Campos-Neto, Raymond Houghton, Thomas S. Vedvick, Daniel R. Twardzik